Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2017 / Feb / Protecting the Last Resort
Microbiology & Immunology Microbiology and Immunology Genetics and epigenetics Omics Molecular Pathology

Protecting the Last Resort

There may be a way to detect resistance to the emergency antibiotic colistin

By William Aryitey 02/23/2017 1 min read

Share

As antimicrobial resistance persists, finding drugs that effectively fight antagonistic microorganisms becomes a more important endeavor. Often referred to as a “last-resort”, the antibiotic colistin combats several multi-drug resistant bacteria – but even it isn’t immune to the creeping cull of resistance. The gene mcr-1, found in species of gut bacteria, gives microbes the ability to resist the effect of colistin, and, worryingly, its protective traits are transmissible both vertically (via genetic fission; common resistance) and horizontally (via plasmids; mobile resistance). Of great concern is the widespread impact that transmission might have if left unchecked. Bacteria that acquire colistin resistance through horizontal, or so-called mobile, transfer of mcr-1 could become untreatable in humans and might also give rise to resistance in other common strains of human-borne bacteria. It goes without saying that detection of the gene is essential in order to contain its escalation – which is where a team of researchers from Germany and Austria step in.

Employing a loop-mediated isothermal amplification (LAMP) system, which uses PCR and WGS, the investigators were able to distinguish plasmid-embedded mcr-1 from vertically-transmitted intrinsic mcr-1 in multi-drug resistant “superbug” Enterobacteriaceae, with 100 percent sensitivity and specificity (1). According to the team, this is the only system to have been shown to accurately differentiate between common and mobile resistance gene transmissions, since they are phenotypically identical. The test takes approximately 20 minutes to carry out with only two minutes of hands-on sample-time needed, and the researchers reiterate that its rapid nature is vital to contain the spread of colistin resistance as effectively as possible. So far, their findings have been taken from bacterial cultures, but the team plans to keep working on the technique to be able to safely implement it as quickly as possible.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. C Imirzalioglu et al., “Evaluation of a LAMP-based assay for the rapid detection of plasmid-encoded colistin resistance gene mcr-1 in Enterobacteriaceae isolates”, Antimicrob Agents Chemother, [Epub ahead of print] (2017). PMID: 28137796.

About the Author(s)

William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

More Articles by William Aryitey

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Context Matters in Cancer Biology
Microbiology and Immunology
Context Matters in Cancer Biology

December 27, 2021

1 min read

Akoya is leading the way with spatial phenotypic signatures – a novel class of biomarkers for predicting response to immunotherapy

What’s New in Infectious Disease? (December 2021)
Microbiology and Immunology
What’s New in Infectious Disease?

December 23, 2021

1 min read

The latest research and news on COVID-19 and the infectious disease landscape

Immunology Insights
Microbiology and Immunology
Immunology Insights

January 13, 2022

1 min read

The latest research in pathology and laboratory medicine

2021: A Laboratory Medicine Roundup
Microbiology and Immunology
2021: A Laboratory Medicine Roundup

January 18, 2022

3 min read

From transgender health care to the power of pathology podcasts, we take a look at our most popular articles of the last year

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.